The Lancet Healthy Longevity is leaving this platform but joining another ⤵️ . You can now find us on.LinkedIn 👉 🌐 And, of course, online at Follow us!.

A retinal biomarker of biological age based on composite clinical phenotypic information – linked Comment by Ruiyang Li and Haotian Lin

Join millions who have switched to Grok.

Application of a deep-learning marker for morbidity and mortality prediction derived from retinal photographs: a cohort development and validation study by Simon Nusinovici and colleagues

Clinical effectiveness of DREAMS START (Dementia Related Manual for Sleep; Strategies for Relatives) vs usual care for people with dementia + their carers: a randomised controlled trial by @rapaport_penny and colleagues

Long-term air pollution exposure and incident physical disability in older US adults: a cohort study by Jiaqi Gao and colleagues

Our October Editorial: Mental health deserves attention at all ages

Our October issue is out! Featuring the DREAMS START trial, air pollution and disability, and much more:

👉If adults with intellectual disability are not included in research on biomarkers for Alzheimer’s disease, then they will not benefit from disease-modifying therapies, as the therapies become more readily available. This would be discrimination through exclusion.

👉Dedicated research programmes are needed to evaluate the diagnostic utility of biomarkers for Alzheimer’s disease this population. These programmes should be designed + adequately powered to explore biomarker dynamics within clinically and biologically homogeneous subgroups.

👉Adults with intellectual disability struggle to access a biomarker-based diagnosis of Alzheimer’s disease. 👉Adults with intellectual disability are not represented in research on biomarkers for Alzheimer’s disease, perpetuating inequity of access to a biomarker-based diagnosis.

Key messages:.👉Adults with intellectual disability are disproportionately affected by dementia. 👉Memory services with specialist expertise for this complex population are necessary, but are currently insufficient.

In the Series on Biomarkers of Neurodegeneration and colleagues discuss biomarkers in the diagnosis of Alzheimer’s disease in adults with intellectual disability

👉Coordinated efforts across research, policy, + cultural realms are needed for a roadmap rooted in equity, inclusivity, and innovation. Efforts should focus on developing infrastructure, implementing culturally sensitive research methods, and ensuring sustainable funding.

👉Major challenges = funding scarcity, infrastructure limitations, and sociocultural barriers in advancing biomarker research.👉Bidirectional collaboration essential for uncovering new insights, improving external validity, and fostering global advancements.

👉Research on biomarkers in Latin America shows promise in diagnosis of Alzheimer’s disease - similar studies in Africa are absent, indicating crucial gaps in research.👉Advancing research in the Global South offers unique opportunities to validate biomarkers in diverse settings.

Key messages:.👉Dementia prevalence is projected to increase 200% rise by 2050 in LMIC highlighting the urgent need for targeted research and care strategies.

In the Series on Biomarkers of Neurodegeneration @EimMcGlinchey and colleagues discuss the evidence on these biomarkers across the Global South

Association between Geriatric 8 frailty and health-related quality of life in older patients with cancer (PROGNOSIS-G8): a Danish single-centre, prospective cohort study by @DitzelHelena and colleagues

And crucially:. 👉Policy makers and health-care systems need to use concrete guidelines for regulating informed and meaningful access to BBs, particularly with the advent of novel treatment strategies.

👉Integration of BBs into health-care settings requires interpreting results across diverse, real-life patient populations.👉Overcoming these challenges is crucial to enable BBs to enhance and democratise the diagnosis and prognosis of Alzheimer’s disease.